The low complexity linker of DNAJB6b is key to its anti-amyloid function
Timas Merkelis1, Ulf Olsson1, Sara Linse2
1Division of Physical Chemistry, Department of Chemistry, Lund University, Lund, Sweden.
QRB Discovery
|December 25, 2025
Summary
The DNAJB6b chaperone inhibits amyloid formation. Its linker region self-assembles but also prevents amyloid aggregation, though less effectively than the full chaperone.
Area of Science:
- Biochemistry
- Molecular Biology
- Neuroscience
Background:
- Neurodegenerative diseases like Alzheimer's and Parkinson's are linked to amyloid fibril formation.
- The DNAJB6b (JB6) chaperone protein inhibits this self-assembly process independently of ATP.
Purpose of the Study:
- To investigate the molecular basis of JB6's anti-amyloid activity.
- To understand the role of the JB6 linker region in amyloid suppression.
Main Methods:
- Studied an isolated 110-amino acid linker construct of JB6.
- Analyzed the linker's structure, aggregation behavior, and anti-amyloid activity.
- Compared the linker's properties to the full-length JB6 chaperone.
Main Results:
- The JB6 linker contains significant alpha-helix and beta-sheet content.
- The linker is an amyloid-like peptide that self-assembles into structures larger than those of the intact chaperone.
- The isolated linker inhibits Aβ42 and α-synuclein fibril formation but is less potent than full-length JB6.
Conclusions:
- JB6's domains likely solubilize the linker, increasing its effective concentration for potent amyloid suppression.
- The self-assembly behavior of the linker contributes to its anti-amyloid mechanism.
- Understanding the linker's role provides insights into neurodegenerative disease mechanisms.
Related Concept Videos
Amyloid Fibrils
11.5K
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
11.5K
Amyloid Fibrils
6.2K
6.2K
Alzheimer's Disease: Overview
1.6K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.6K
Covalently Linked Protein Regulators
8.6K
Proteins can undergo many types of post-translational modifications, often in response to changes in their environment. These modifications play an important role in the function and stability of these proteins. Covalently linked molecules include functional groups, such as methyl, acetyl, and phosphate groups, and also small proteins, such as ubiquitin. There are around 200 different types of covalent regulators that have been identified.
These groups modify specific amino acids in a protein....
These groups modify specific amino acids in a protein....
8.6K
Covalently Linked Protein Regulators
2.0K
2.0K
Alzheimer's Disease: Treatment
744
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
744


